Evidence map›Paper›PMID 33340264›Full record

Observational studyPharmacology research & perspectives2021

Patients receiving a high burden of antibiotics in the community in Spain: a cross-sectional study.

Rocío Fernández-Urrusuno, Carmen Marina Meseguer Barros, Sonia Anaya-Ordóñez, Yolanda Borrego Izquierdo, María Jesús Lallana-Álvarez, Rosa Madridejos, Esther Marco Tejón, Raquel Prieto Sánchez, Olatz Pérez Rodríguez, María García Gil and 12 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Pharmacology research & perspectives, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Decalogue for the selection of oral antibiotics for lower respiratory tract infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022
    Review
  10. Article
  11. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 13 institutions in 2 countries.

Rocío Fernández-UrrusunoClinical Unit Primary Care Pharmacy Sevilla, Aljarafe-Sevilla Norte Primary Health Area, Andalusian Health Service, Seville, Spain.ORCID 0000-0002-6261-6869
Carmen Marina Meseguer BarrosService of Pharmacy, Ouest Primary Health Care Area, Madrid Health Service, Madrid, Spain.
Sonia Anaya-OrdóñezService of Pharmacy, Granada Metropolitano Primary Health Care Area, Andalusian Health Service, Granada, Spain.
Yolanda Borrego IzquierdoCantabria Primary Care Management, Cantabrian Health Service, Santander, Spain.
María Jesús Lallana-ÁlvarezService of Primary Care Pharmacy, Aragón Health Service, Zaragoza, Spain.
Rosa MadridejosService of Pharmacy, Mutua Terrasa, Barcelona, Spain.
Esther Marco TejónCuenca Primary Care Management, Hospital Virgen de la Luz, Castilla La Mancha Health Service, Cuenca, Spain.
Raquel Prieto SánchezCantabria Primary Care Management, Cantabrian Health Service, Santander, Spain.
Olatz Pérez RodríguezMallorca Primary Care Management, Islas Baleares Health Service IB-SALUT, Palma de Mallorca, Spain.
María García GilService of Pharmacy, Sagunto Health Care Area, Comunidad Valenciana, Valencia, Spain.
Belén Escudero VilaplanaService of Pharmacy, Ouest Primary Health Care Area, Madrid Health Service, Madrid, Spain.
Genma M Silva RiádigosService of Pharmacy, Ouest Primary Health Care Area, Madrid Health Service, Madrid, Spain.
M Sagrario Pardo López-FandoService of Pharmacy, North Primary Health Care Area, Madrid Health Service, Madrid, Spain.
Vicente Olmo QuintanaService of Pharmacy, Gran Canaria Primary Care Management, Canarian Health Service, Gran Canaria, Spain.
M Belén Pina GadeaService of Primary Care Pharmacy, Aragón Health Service, Zaragoza, Spain.
Angel García AlvarezTramuntana Primary Care Management, Islas Baleares Health Care Service, Palma de Mallorca, Spain.
M Llüisa Sastre MartorellService of Pharmacy, Hospital Universitari Son Espases, Islas Baleares Health Service IB-SALUT, Palma de Mallorca, Spain.
Jorge I Jiménez ArceClinical Unit Primary Care Pharmacy Area VII Asturias, Principado de Asturias Health Service, Mieres, Asturias, Spain.
Rafael Aguilella VizcaínoService of Pharmacy, North Primary Health Care Area, Madrid Health Service, Madrid, Spain.
Joaquín Pérez MartínFaculty of Social Sciences, Area of Design, Gaming and Multimedia, European University of Madrid, Madrid, Spain.
Natalia Alzueta IsturizUnit of Drug Assessment, Advice and Research, Navarra Health Service, Pamplona, Spain.
Infectious Diseases SEFAP team
Madrid Health Service · ESAndalusian Health Service · ESServei de Salut de les Illes Balears · ESServicio Aragonés de Salud · ESUniversidad de Cantabria · ESGeneralitat Valenciana · ESGobierno de Canarias · ESGobierno del Principado de Asturias · ESHospital Universitario Son Espases · ESHospital Virgen de la Luz · ESUniversidad de Navarra · ESUniversidad Europea de Madrid · ESUniversity Hospital Mútua de Terrassa · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Some patients in the community receive a high burden of antibiotics. We aimed at describing the characteristics of these patients, antibiotics used, and conditions for which they received antibiotics. We carried out a cross-sectional study. Setting: Thirty Health Primary Care Areas from 12 regions in Spain, covering 5,960,191 inhabitants. Patients having at least 30 packages of antibacterials for systemic use dispensed in 2017 were considered. Main outcome measures: Prevalence of antibiotic use, conditions for which antibiotics were prescribed, clinical characteristics of patients, comorbidities, concomitant treatments, and microbiological isolates. Patient's average age was 70 years; 52% were men; 60% smokers/ex-smokers; 54% obese. Overall, 93% of patients had, at least, one chronic condition, and four comorbidities on average. Most common comorbidities were cardiovascular and/or hypertension (67%), respiratory diseases (62%), neurological/mental conditions (32%), diabetes (23%), and urological diseases (21%); 29% were immunosuppressed, 10% were dead at the time of data collection. Patients received three antibiotic treatments per year, mainly fluoroquinolones (28%), macrolides (21%), penicillins (19%), or cephalosporins (12%). Most frequently treated conditions were lower respiratory tract (infections or prophylaxis) (48%), urinary (27%), and skin/soft tissue infections (11%). Thirty-five percent have been guided by a microbiological diagnosis, being Pseudomonas aeruginosa (30%) and Escherichia coli (16%) the most frequent isolates. In conclusion, high antibiotic consumers in the community were basically elder, with multimorbidity and polymedication. They frequently received broad-spectrum antibiotics for long periods of time. The approach to infections in high consumers should be differentiated from healthy patients receiving antibiotics occasionally.

Indexed as

AgedAged, 80 and overAnti-Bacterial AgentsCommunicable DiseasesCross-Sectional StudiesDrug PrescriptionsDrug UtilizationFemaleHumansMaleMiddle AgedPolypharmacySpainAnti-Bacterial Agentsambulatory Careantibiotic prescribingantimicrobial stewardship programsinfectionoutpatients

Identifiers

PMID33340264
PMCPMC7749514
OpenAlexW3113601412

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.